An Observational Study to Evaluate Cardiovascular Outcomes of Patients With Type 2 Diabetes Mellitus Treated With Gemigliptin
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Gemigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors LG Chem; LG Life Sciences
- 27 Jan 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 27 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 18 Nov 2014 New trial record